SCHEMBL13178587

SCHEMBL13178587

CC(C)=CCOc1cc(Nc2nccc3ccccc23)ccc1C#N

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 3/20 0.39
IMPDH2 P12268 1/20 0.36
HDAC3 O15379 2/20 0.36
HDAC1 Q13547 2/20 0.36
HDAC6 Q9UBN7 2/20 0.36
GRM4 Q14833 1/20 0.36
HPGD P15428 2/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
NPC1 O15118 1/20 0.35
ALDH1A1 P00352 1/20 0.35
CASP3 P42574 1/20 0.35
RAB9A P51151 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
SENP8 Q96LD8 1/20 0.35
SENP7 Q9BQF6 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14540874 0.85 PDGFRB (0.42) EGFRHDAC3HDAC1HDAC6GRM4
SCHEMBL13138552 0.84 ABCG2 (0.54) EGFRNPC1RAB9ASMN1; SMN2ERBB2
SCHEMBL13138562 0.83 ALDH1A1 (0.38) IMPDH2HPGDCYP1A2CYP3A4CYP2D6
SCHEMBL13138556 0.83 FADS1 (0.43) EGFRIMPDH2HPGDCYP1A2CYP3A4
SCHEMBL5408787 0.81 IMPDH2 (0.40) IMPDH2KMT2AABCG2
SCHEMBL16671997 0.78 EGFR (0.35) EGFRIMPDH2ALDH1A1ABCG2
SCHEMBL13138567 0.78 BCL6 (0.39) EGFRIMPDH2HPGDCYP1A2CYP3A4
SCHEMBL16356879 0.78 IGF1R (0.39) IMPDH2ALDH1A1KMT2ASYK
SCHEMBL13178586 0.77 FDPS (0.42) EGFRHDAC3HDAC1HDAC6GRM4
SCHEMBL3047670 0.75 PLA2G7 (0.40) NPC1RAB9ASMN1; SMN2NPSR1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9018209-B2 Compounds and methods for the treatment of viruses and cancer YALE UNIVERSITY (US) 2015-04-28 US disclosed
US-9018209-B2 Compounds and methods for the treatment of viruses and cancer YALE UNIVERSITY (US) 2015-04-28 US disclosed
US-20100222352-A1 Compounds and Methods for the Treatment of Viruses and Cancer YALE UNIVERSITY (US) 2010-09-02 US disclosed
WO-2007038387-A2 COMPOUNDS AND METHODS FOR THE TREATMENT OF VIRUSES AND CANCER YALE UNIVERSITY (US) 2007-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100222352-A1 Compounds and Methods for the Treatment of Viruses and Cancer RCOR1, RCOR3, CCNT1 EGFR 224/4885IMPDH2 3184/4885HDAC3 164/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.